LS

Lalitkumar Sudhir Zambre

Active Director Designated Partner DIN 10964981
DIN 10964981 First appointment Feb 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Lalitkumar Sudhir Zambre

Data last updated:

Lalitkumar Sudhir Zambre is a Designated Partner at Kyroderm Pharmaceutical Llp (since 2025).

DIN 10964981
Primary Designation Designated Partner
First Appointment 22 Feb 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner22 Feb 20252025Active

Board colleagues of Lalitkumar Sudhir Zambre

NameDINCompanyDesignation
Sukrutta Desai02865672Kyroderm Pharmaceutical LlpDesignated Partner
Umesh Changdev Bhosale10964982Kyroderm Pharmaceutical LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Kyroderm Pharmaceutical Llp
Premium access

Shareholding and investment profile for Lalitkumar Sudhir Zambre

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Lalitkumar Sudhir Zambre

Lalitkumar Sudhir Zambre currently holds 1 directorship: Kyroderm Pharmaceutical Llp (Designated Partner, since 22 Feb 2025).

Lalitkumar Sudhir Zambre was first appointed on 22 Feb 2025 as Designated Partner at Kyroderm Pharmaceutical Llp.

The current boards of Lalitkumar Sudhir Zambre's companies include Sukrutta Desai (Kyroderm Pharmaceutical Llp), Umesh Changdev Bhosale (Kyroderm Pharmaceutical Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available